Servier $210m bet on IDEAYA’s uveal melanoma therapy darovasertib seems to have paid off, as a trial sets up regulatory filings later in 2026.

Revolution Medicines reported Monday that its experimental KRAS inhibitor called daraxonrasib succeeded in a registrational trial for pancreatic cancer. And now, the company plans to

AstraZeneca’s hyperkalaemia drug Lokelma could see its use by the NHS more than double thanks to updated guidance from NICE.

Ideaya’s late-stage data for a rare eye cancer drug has passed the company’s benchmark for success, bolstering expectations for a planned accelerated filing in the

GSK’s B7-H4-targeting ADC Mo-Rez chalks up impressive results in ovarian and endometrial cancer, prompting a major phase 3 trials programme.